Bamco Inc Adaptimmune Therapeutics PLC Transaction History

Bamco Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$1.43 - $3.81 $246,916 - $657,868	-172,669 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$3.23 - $5.41 $32,300 - $54,100	10,000 Added 6.15%	172,669 $694,000
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $1.67 Million - $6.3 Million	-445,030 Reduced 73.23%	162,669 $935,000
Q3 2018 Nov 14, 2018	BUY	$8.27 - $13.56 $2.17 Million - $3.56 Million	262,330 Added 75.96%	607,699 $8.24 Million
Q2 2018 Aug 14, 2018	BUY	$10.42 - $13.74 $3.6 Million - $4.75 Million	345,369 New	345,369 $4.1 Million

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $105M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Bamco Inc , based on Form 13F filings with the SEC.

Stay updated on Bamco Inc with notifications on news.